Breast Tumor
35
5
7
9
Key Insights
Highlights
Success Rate
69% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.4%
4 terminated out of 35 trials
69.2%
-17.3% vs benchmark
3%
1 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (35)
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.
3D Ultrasound Breast Imaging
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Proton Radiation for Stage II/III Breast Cancer
Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy
Metastatic Breast Cancer in Austria
Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery
The Treatment Situation of Chinese County Population With Breast Cancer
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI
Breast Tumor Oxygenation During Exercise